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Summary
 
The adoptive transfer of naive CD4
 
1
 
 T cell receptor (TCR) transgenic T cells was used to in-
vestigate the mechanisms by which the adjuvant lipopolysaccharide (LPS) enhance T cell clonal
expansion in vivo. Subcutaneous administration of soluble antigen (Ag) resulted in rapid and
transient accumulation of the Ag-specific T cells in the draining lymph nodes (LNs), which was
preceded by the production of interleukin (IL)-2. CD28-deficient, Ag-specific T cells pro-
duced only small amounts of IL-2 in response to soluble Ag and did not accumulate in the LN
to the same extent as wild-type T cells. Injection of Ag and LPS, a natural immunological ad-
juvant, enhanced IL-2 production and LN accumulation of wild-type, Ag-specific T cells but
had no significant effect on CD28-deficient, Ag-specific T cells. Therefore, CD28 is critical for
Ag-driven IL-2 production and T cell proliferation in vivo, and is essential for the LPS-medi-
ated enhancement of these events. However, enhancement of IL-2 production could not ex-
plain the LPS-dependent increase of T cell accumulation because IL-2–deficient, Ag-specific T
cells accumulated to a greater extent in the LN than wild-type T cells in response to Ag plus
LPS. These results indicate that adjuvants improve T cell proliferation in vivo via a CD28-
dependent signal that can operate in the absence of IL-2.
 
C
 
lonal expansion of Ag-specific T cells during a pri-
mary immune response is critical for the development
of subsequent immunological memory (1). However, ex-
pansion of Ag-specific T cells after exposure to a soluble for-
eign Ag is typically only transient and is quickly followed
by the deletion and/or functional inactivation of the cells
(2, 3). Such abortive immune responses can be rescued by
the addition of immunological adjuvants that increase the
proliferation of Ag-specific T cells and prolong their sur-
vival and functional competence (1–4). Multiple substances
have adjuvant properties, but the mechanisms responsible
for adjuvanticity are poorly understood.
Because adjuvants increase the number of Ag-specific T
cells that accumulate in lymphoid tissues, it is likely that
they affect T cell growth factor production. In vitro studies
have established that IL-2 is a potent T cell growth factor
(5) and that at least two signals are required for optimal IL-2
production: one provided by the interaction of the TCR
with peptide–class II MHC complexes, and the second by
binding of costimulatory molecules like CD28 to B7-1 and
B7-2, present on APCs (6, 7). Because adjuvants have been
shown to induce B7 molecules on APCs (8, 9), it is possi-
ble that adjuvants improve the costimulatory functions of
APCs, which stimulate T cells to produce more IL-2 and
proliferate more extensively. Here, we tested this model by
studying the clonal expansion of wild-type, CD28-defi-
cient, or IL-2–deficient TCR transgenic T cells in vivo af-
ter adoptive transfer into normal recipients and priming
these recipients with Ag plus or minus adjuvant. Our re-
sults lead to the surprising conclusion that adjuvants im-
prove T cell clonal expansion via CD28-mediated enhance-
ment of a growth factor other than IL-2. In fact, IL-2
appeared to play an inhibitory role because the long-term
persistence of Ag-specific T cells after antigenic challenge
in vivo was actually improved in the absence of IL-2.
 
Materials and Methods
 
Mice and the Adoptive Transfer Protocol.
 
BALB/c mice were
purchased from Sasco (Omaha, NE) or The Jackson Laboratories
(Bar Harbor, ME). The DO11.10 TCR transgenic mice (10)
were bred in a specific pathogen-free facility according to Na-
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tional Institutes of Health guidelines, and screened for transgene
expression as previously described (2). These mice had been ex-
tensively backcrossed (
 
.
 
15 generations) onto the BALB/c back-
ground and, therefore, are histocompatible with normal BALB/c
mice. CD4
 
1
 
, KJ1-26
 
1
 
 TCR transgenic cells were adoptively
transferred (2.5–5
 
 3 
 
10
 
6 
 
cells per mouse) by intravenous injection
into unirradiated BALB/c mice as previously described (2). CD28-
deficient mice (generously provided by Dr. Craig B. Thompson,
University of Chicago, IL) were backcrossed to DO11.10 BALB/c
mice for five generations. No evidence for rejection of transferred
CD28-deficient DO11.10 T cells was seen in any of the experi-
ments (over a time course of eight days). DO11.10 BALB/c mice
were crossed for two generations with BALB/c SCID mice ob-
tained from The Jackson Laboratories to produce DO11.10 TCR
transgenic BALB/c SCID donors. IL-2 
 
1
 
/
 
2
 
 BALB/c mice, ob-
tained from The Jackson Laboratories, were crossed for two gen-
erations with the DO11.10 mice and screened by PCR for the
presence of the targeted IL-2 gene and by flow cytometry for the
presence of the DO11.10 TCR. The IL-2–deficient DO11.10
mice were not observed to have overt clinical manifestations of
an autoimmune disease described in the BALB/c IL-2–deficient
mice (11) for at least 3 mo, although they did develop lymphade-
nopathy and splenomegaly. Furthermore, the dominant population
of CD4
 
1
 
, KJ1-26
 
1
 
 cells in these mice had the surface phenotype of
naive cells, that is, CD45RB
 
high
 
, LFA
 
low
 
, CD69
 
low
 
 (data not shown).
 
Adoptive Transfer of CD45RB
 
high
 
 and CD45RB
 
low
 
 DO11.10 T
Cells.
 
A subpopulation of transgenic DO11.10 T cells expressed
a second TCR and were CD45RB
 
low
 
 due to previous activation
(12). LN and spleen cells were obtained from wild-type and IL-
2–deficient DO11.10 mice. Cells were stained and sorted simi-
larly, with some modifications, to a protocol described by Powrie
et al. (13). In brief, erythrocytes were removed by hypotonic lysis
using ACK Buffer (Biofluids, Inc., Rockville, MD) and CD4
 
1
 
T cells were enriched by negative depletion using magnetic beads
(Dynal, Oslo, Norway) coated with anti-B220, anti-CD8, anti-I-A
 
d
 
,
and anti-HSA. The anti-HSA mAb proved critical for efficient
enrichment of cells obtained from IL-2–deficient mice because of
the greatly expanded population of HSA
 
1
 
 cells negative for other
markers in these mice (11). Enriched CD4
 
1
 
 T cells (75–95% pure)
were labeled with FITC-conjugated anti-CD45RB mAb for 15
min on ice and separated into CD45RB
 
high 
 
and CD45RB
 
low
 
 frac-
tions by single-color sorting on a FACSVantage
 
Ò
 
 flow cytometer
(Becton Dickinson, Mountain View, CA). Sorted cells were then
transferred into syngeneic BALB/c recipients as described above.
 
Flow Cytometric Analysis of LN Cells.
 
Chicken OVA (Sigma
Chemical Co., St. Louis, MO) was injected subcutaneously (typi-
cally 2 mg with or without 50–150 
 
m
 
g of LPS; serotype 
 
Escheri-
chia coli
 
 026:B6; Difco Laboratories, Detroit, MI) into four sites
on the back. Axillary, brachial, and inguinal LNs were harvested
at various times, and the transferred DO11.10 T cells were identi-
fied by two-color flow cytometric analysis as previously described
(2). In brief, 2
 
 3 
 
10
 
6
 
 LN cells were incubated on ice with PE-labeled
anti-CD4 mAb (PharMingen, San Diego, CA) and biotinylated
KJ1-26 mAb, which binds exclusively to the DO11.10 TCR.
Cells were then washed and incubated with FITC-labeled streptavi-
din (SA; Caltag, South San Francisco, CA) to detect the KJ1-26
mAb. 20,000 events were then collected for each sample on a
FACScan
 
Ò
 
 flow cytometer and analyzed using Lysis II software.
DO11.10 T cells were identified as CD4
 
1
 
, KJ1-26
 
1
 
 cells. The
total number of DO11.10 T cells present was calculated by multi-
plying the total number of viable LN cells (obtained by counting
viable cells) by the percentage of CD4
 
1
 
, KJ1-26
 
1
 
 cells obtained
by flow cytometry.
 
Reverse Transcription PCR.
 
Total RNA was isolated from LN
cell suspensions according to the RNAzol B procedure (Tel-Test,
Inc., Friendswood, TX). In some cases, the LN cells were de-
pleted of DO11.10 cells using the KJ1-26 mAb and magnetic
beads according to the manufacturer’s protocol. 2 
 
m
 
g of total
RNA were used in an oligo-dT–mediated reverse transcription
(RT)–PCR in a total volume of 20 
 
m
 
l. One-tenth of the result-
ing cDNA was amplified by PCR as previously described with
sense and antisense primers derived from the 
 
IL-2 
 
gene or the 
 
hy-
poxanthine-guanine phosphoribosyl transferase (HPRT)
 
1
 
 
 
gene, which
was used as internal control (14). PCR products were then sepa-
rated on 1% agarose gels, transferred to nylon membranes, de-
tected by conventional Southern blot techniques with 
 
32
 
P-labeled
 
IL-2
 
 and 
 
HPRT 
 
cDNA probes, and then visualized by autoradi-
ography. In some experiments, the cDNAs were amplified with
the IL-2 and HPRT primer sets in the same reaction in the pres-
ence of 
 
a
 
-[
 
32
 
P]dCTP (0.2 
 
m
 
Ci/tube). The PCR products were
then separated on 5% urea–polyacrylamide gels, visualized by au-
toradiography, and then analyzed by densitometry. Because the
PCR reactions were still in the linear range for both HPRT and
IL-2 products (23 cycles), the optical units (OU) obtained for the
HPRT bands were used as an internal standard for the total
amount of RNA/cDNA used in each reaction. The amount of
OVA-induced IL-2 mRNA was then calculated according to the
following formula: [OU (IL-2) / OU (HPRT)]injected
 
 
 
2
 
 [OU
(IL-2) / OU (HPRT)]uninjected. Since IL-2 mRNA produced by
endogenous OVA-specific T cells cannot be detected by this
technique (Mondino, A., unpublished observations) all of the
OVA-induced IL-2 mRNA measured must be derived from the
transferred DO11.10 T cells.
 
IL-2 Protein Intracellular Staining.
 
A staining protocol based on
work of others (15) was used to detect IL-2 production by trans-
ferred DO11.10 T cells. LN cells (3
 
 3 
 
10
 
6
 
) isolated at various
times after Ag injection were stained with anti-CD4 Cy-Chrome
and biotinylated KJ1-26, followed by SA-FITC in staining buffer
(PBS plus 2% fetal calf serum and 0.2% sodium azide). The cells
were then washed with PBS, fixed for 20 min at room tempera-
ture in PBS containing 2% formaldehyde, permeabilized with
two washes in staining buffer containing 0.5% saponin (Sigma
Chemical Co.), and then incubated for 30 min at room tempera-
ture with PE-labeled anti–IL-2 mAb, or with a PE-labeled irrele-
vant mAb of the same isotype (PharMingen). The cells were then
washed once with saponin buffer and twice with PBS, and at least
1,000 CD4
 
1
 
, KJ1-26
 
1
 
 events (as well as an equal number of CD4
 
1
 
,
KJ1-26
 
2
 
 events) were collected for each sample on a FACScan
 
Ò
 
flow cytometer. For most experiments the amount of intracellular
IL-2 protein present after OVA injection was calculated as the
percentage increase in the mean fluorescence intensity (MFI) of
IL-2–stained CD4
 
1
 
, KJ1-26
 
1
 
 cells according to the following
formula: [(MFI
 
injected
 
 
 
2
 
 MFI
 
uninjected
 
) / MFI
 
uninjected
 
] 
 
3
 
 100.
It should be noted that LN cells were stained immediately after
isolation. No additional incubation in the presence of Brefeldin
A, an inhibitor of exocytosis important for detection of intracel-
lular cytokines produced in response to in vitro stimulation (15),
was required since this compound did not enhance the amount of
intracellular IL-2 detected in freshly explanted LN cells. How-
ever, Brefeldin A did prevent the loss of intracellular IL-2 that
 
1
 
Abbreviations used in this paper:
 
 
 
g
 
c
 
, common 
 
g
 
 chain; HPRT, hypoxan-
thine-guanine phosphoribosyl transferase; MFI, mean fluorescence inten-
sity; OU, optical units; RT, reverse transcription; SA, streptavidin. 
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occurred when LN cells were incubated in vitro at 37
 
8
 
C for an
additional 2–3 h (Khoruts, A., unpublished observations).
 
ELISA Measurement of IL-2 Production by DO11.10 T Cells Af-
ter In Vivo OVA Stimulation.
 
LN cells (3–5
 
 3 
 
10
 
6
 
) from OVA-
injected or uninjected adoptive transfer recipients were suspended
in 0.2 ml of complete medium (Eagle’s Hanks’ amino acids me-
dium; Biofluids) supplemented with 10% FCS, penicillin G (100
U/ml), streptomycin (100 
 
m
 
g/ml), gentamicin (20 
 
m
 
g/ml),
 
L
 
-glutamine (2
 
 3 
 
10
 
2
 
3
 
 M), and 2-mercaptoethanol (5
 
 3 
 
10
 
2
 
5
 
 M),
and incubated in vitro at 37
 
8
 
C without additional Ag for 2–4 h.
IL-2 secreted into the supernatant was measured by sandwich
ELISA based on noncompeting pairs of anti–IL-2 mAbs, JES6-
1A12 and JES6-5H4 (PharMingen) according to the protocol
provided by the manufacturer. IL-2 was not detected in the cul-
ture supernatants of LN cells from Ag-primed animals that did
not receive DO11.10 T cells (Khoruts, A., and A. Mondino, un-
published observation). Since the IL-2 signal was completely de-
pendent on the presence of DO11.10 T cells, the mean amount
of IL-2 secreted by individual DO11.10 cells was calculated by
dividing the amount of IL-2 produced in the culture by the num-
ber of CD4
 
1
 
, KJ1-26
 
1
 
 cells present.
 
Measurement of IL-2, IL-3, IL-5, and IFN-
 
g
 
 
 
Production after In
Vitro Ag Stimulation Using ELISA.
 
LN cells (2.5
 
 3 
 
10
 
6
 
) from
OVA/LPS-injected or uninjected adoptive transfer recipients were
suspended in 0.25 ml of complete medium and incubated in the
presence or absence of 10 
 
m
 
M OVA peptide 323-339 for 48 h.
Cytokines present in the culture medium were measured by sand-
wich ELISA based on noncompeting pairs of anti–IL-2 (JES6-
1A12 and JES6-5H4), anti–IL-3 (MP2-8F8 and MP2-43D11), anti–
IL-5 (TRFK5 and TRFK4), or anti–IFN-
 
g
 
 mAbs (R4-6A2 and
XMG1.2; PharMingen) according to the protocol provided by
the manufacturer. IL-2 could not be detected after stimulation of
IL-2–deficient DO11.10 T cells, and cytokine production was de-
pendent on addition of the OVA peptide. Amounts of cytokine
produced were either calculated based upon the standard curve
generated by known amounts of cytokine, or expressed as relative
units based upon OD values. All cytokine concentrations were
then adjusted for the number of CD4
 
1
 
, KJ1-26
 
1
 
 cells present at
the start of the culture period.
 
In Vivo Ab Treatments.
 
Rat mAbs specific for murine B7-1
(1G10) or B7-2 (GL-1) were generously provided by Dr. Bruce
Blazar (University of Minnesota, Minneapolis, MN). Anti-B7 or
rat IgG control antibodies were injected intravenously into mice
6 h before Ag administration and intraperitoneally at the time of
Ag administration (75 
 
m
 
g/injection). CTLA-4–Ig fusion protein
(kindly provided by Dr. Robert Karr, Monsanto Company, St.
Louis, MO) was purified over protein A–agarose. CTLA-4–Ig
was injected intravenously (100 
 
m
 
g/injection) 6 h before Ag ad-
ministration and intraperitoneally at the time of Ag administra-
tion. Neutralizing anti–IL-2 mAb S4B6 or rat IgG control anti-
bodies were injected 2 h before (1 mg) and 8, 24, and 48 h (0.5
mg) after Ag administration.
 
Results
 
Quantitative Detection of IL-2 mRNA and Protein In Vivo
after Injection of Soluble OVA.
 
The adoptive transfer sys-
tem used here allowed physical tracking of Ag-specific
CD4
 
1
 
 T cells during OVA-induced immune responses in
vivo (2). CD4
 
1
 
 T cells obtained from OVA peptide/I-A
 
d
 
–
specific, DO11.10 TCR transgenic mice were transferred
into otherwise unmanipulated syngeneic BALB/c recipi-
ents. The DO11.10 T cells were detected with the anticlo-
notypic mAb, KJ1-26, by flow cytometry (2). Clonal ex-
pansion of transferred DO11.10 T cells in response to
soluble Ag injection was greatly enhanced by immunologi-
cal adjuvants such as CFA (2) or LPS (Fig. 1 and reference
4). This increase was apparent at all time points examined
including the time of peak DO11.10 T cell accumulation
on day 3, and on days when the number of DO11.10 T
cells had decreased slightly (day 5) or dramatically (day 12).
A mechanism by which adjuvants could affect T cell
clonal expansion is enhancement of growth factor produc-
tion. IL-2 was studied because it is the major T cell growth
factor produced by naive CD4
 
1
 
 T cells after stimulation in
vitro (16), and IL-2–deficient CD4
 
1
 
 T cells proliferate less
well than normal CD4
 
1
 
 T cells after activation (17–19).
Production of IL-2 mRNA by the DO11.10 T cells was
investigated using RT-PCR (Fig. 2 
 
A
 
). Injection of soluble
OVA resulted in a marked increase in IL-2 mRNA expres-
sion in the draining LN cells of adoptive transfer recipients
(Fig. 2 
 
A
 
, 
 
LN Cells
 
). The OVA-induced IL-2 mRNA was
exclusively expressed by the DO11.10 T cells because the
inducible signal was lost whenever RNA was isolated from
LN cells depleted of DO11.10 T cells with KJ1-26–coated
magnetic beads (Fig. 2 
 
A
 
, 
 
KJ1-26 Depleted
 
) and retained
when RNA was isolated from the cells that adhered to the
KJ1-26–coated beads (Fig. 2 
 
A
 
, 
 
Beads
 
).
Intracellular staining was used to detect IL-2 protein (15,
20). IL-2 protein was detected in a subset of CD4
 
1
 
, KJ1-
261 T cells (identified as shown in Fig. 2 B) recovered from
mice injected subcutaneously 10 h before with OVA (Fig.
2 C, histogram 3). No staining was detected in CD41,
KJ1-262 T cells present in the same tube (Fig. 2 C, histo-
gram 2), in CD41
, KJ1-261 T cells stained with an isotype-
matched control mAb (Fig. 2 C, histogram 1), or in CD41,
Figure 1. LPS increases CD41, KJ1-261 clonal expansion. The total
number of CD41, KJ1-261 cells was measured in the draining LNs (axil-
lary, brachial, inguinal, and cervical) after s.c. injection of 2 mg OVA
without (open circles) or with LPS (filled circles). One representative experi-
ment of 15 is shown.228 Roles of Adjuvant, CD28, and IL-2 during Primary T Cell Responses In Vivo
KJ1-261 T cells recovered from animals that received no
Ag and were stained with anti–IL-2 mAb (Fig. 2 C, histo-
gram 4). Analysis of OVA-induced IL-2 production over
time by DO11.10 T cells indicated that IL-2 mRNA ex-
pression peaked 10 h after Ag administration and was barely
detectable by 24 h (Fig. 2 D). Very similar results were re-
ported by Rogers et al. (21), who used this adoptive trans-
fer system to detect IL-2 mRNA in situ. As expected, IL-2
protein production lagged behind mRNA production, with
peak expression occurring 12-14 h after OVA injection and
returning to background levels after 24 h (Fig. 2 D). These
results indicate that IL-2 production by OVA-specific T cells
after Ag encounter in vivo occurs in a very rapid and tran-
sient fashion. Because the transferred DO11.10 T cells con-
tain a subpopulation of cells (10–30% of the transgenic
cells) with a memory phenotype presumably due to activa-
tion through a second TCR (12), we repeated the kinetics
experiments using adoptively transferred DO11.10 SCID T
cells, which are all of naive phenotype. The kinetics of IL-2
production by these cells was indistinguishable from that of
wild-type DO11.10 T cells (data not shown), thereby ex-
cluding the possibility of memory cells contributing signifi-
cantly to the earliest production of IL-2 in this system.
IL-2 Production In Vivo Is Enhanced by LPS and Is Depen-
dent on B7-CD28. Injection of soluble Ag with LPS re-
sulted in increased IL-2 production by the Ag-specific cells.
Figure 2. Ag-specific CD41 T cells express IL-2 mRNA and protein after Ag injection. (A) Adoptively transferred mice were either uninjected (2) or
injected subcutaneously with soluble OVA (1). Peripheral LNs were harvested 6 h after Ag injection. Total RNA was obtained from unfractionated LN
cells (LN Cells), from cells that were depleted of DO11.10 T cells by KJ1-26 mAb-coated magnetic beads (KJ1-26 depleted), and from magnetic bead-
enriched KJ1-261 cells (Beads). IL-2 and HPRT RT-PCR products were detected by Southern blot and autoradiographic techniques. (B) BALB/c mice
were injected with 2.5 3 106 DO11.10 T cells as described in the Materials and Methods section. FACSÒ profiles for brachial, axillary, and inguinal LN
cells from normal (left) or adoptive transfer mice (right) stained with Cy-Chrome–labeled anti-CD4 mAb and FITC-labeled KJ1-26 mAb are shown. (C)
Cells in B, right were further stained with PE-labeled anti–IL-2 mAb. Histograms represent PE-channel fluorescence of stained LN cells recovered from
uninjected (histogram 2) or OVA-injected animals (histograms 1, 3, and 4). Histogram 1, CD41, KJ1-261 cells stained with PE-labeled isotype matched
mAb (rat IgG2a); histogram 2, CD41, KJ1-261 cells from an uninjected mouse stained with PE-labeled anti–IL-2 mAb; histograms 3 and 4, CD41, KJ1-
261 and CD41, KJ1-262 cells stained with PE-labeled anti–IL-2 mAb. (D) The kinetics of IL-2 mRNA (open circles) and protein (filled circles) expression
after s.c. injection of 2 mg OVA. Data from three separate experiments on the kinetics of IL-2 mRNA expression were pooled. IL-2 mRNA was de-
tected by RT-PCR and quantified as described in Materials and Methods. Each point represents the mean from 4–10 mice 6 SEM. IL-2 protein expres-
sion was measured as described in B and C. One representative experiment of four is shown. Each point represents the mean of two mice 6 range.229 Khoruts et al.
The effect of LPS was attributable to an increased number
of DO11.10 T cells that produced IL-2 (Table 1, lane A)
and to greater IL-2 production per DO11.10 T cell (Table
1, lane B and Fig. 3). A similar adjuvant effect was seen
when DO11.10 SCID T cells were used in the adoptive
transfer (data not shown) demonstrating that naive T cells
are the predominant adjuvant-responsive population. The
two- to threefold difference in the relative increase in mean
fluorescence intensity of IL-2 staining correlated with the
differences in IL-2 detected by ELISA in the supernatants
of LN cells cultured in vitro in the absence of additional
antigenic stimulation (Fig. 3).
It has been proposed that adjuvants enhance T cell re-
sponses by increasing the expression of costimulatory mole-
cules on APC (6, 8). If LPS works by this mechanism, then
its adjuvanticity should be diminished in the absence of
CD28-mediated costimulation. This prediction was tested
using adoptive transfer of CD28-deficient DO11.10 T cells.
As shown in Fig. 4, CD28-deficient DO11.10 T cells pro-
duced small, but significant, amounts of IL-2 in vivo in re-
sponse to OVA when compared with wild-type DO11.10
T cells. The CD28-deficient DO11.10 T cells were defec-
tive at producing IL-2 at each time point tested over the
first 20 h after Ag injection. The CD28-deficient DO11.10
T cells did become blasts (Fig. 4 C), however, demonstrat-
ing that these cells were stimulated by Ag-bearing APCs in
vivo. LPS did not significantly enhance the amount of IL-2
produced by CD28-deficient DO11.10 T cells in response
to OVA (Fig. 4, A and B, Table 1). Similarly, when B7
molecules were blocked in vivo with CTLA-4–Ig (Table 1)
or a combination of anti–B7-1 and anti–B7-2 mAbs (data
not shown), OVA-induced IL-2 production by DO11.10
T cells was dramatically reduced regardless of the presence
of adjuvant (Table 1). These results indicate that LPS en-
hances Ag-driven IL-2 production through a B7/CD28-
dependent signal.
The lack of an adjuvant effect of LPS on IL-2 produc-
tion by CD28-deficient DO11.10 T cells correlated well
with the lack of an adjuvant effect of LPS on the expansion
of these cells (Fig. 4 D). Interestingly, CD28-deficient
DO11.10 T cells retained substantial ability to expand in re-
sponse to soluble Ag in the absence of adjuvant. Since a
Table 1. Pooled Data on IL-2 Production by CD41, KJ1-261 Cells In Vivo in Response to Ovalbumin 6 LPS
Treatment
group
Mice
per
group Lane
Parameter of IL-2
staining of CD41,
KJ1-261 cells No Antigen OVA OVA/LPS
OVA
versus
OVA/LPS
mean 6 SE mean 6 SE mean 6 SE
Control mice: Rat IgG n 5 39 A Percentage of 0.22 6 0.03 10.7 6 0.6 22.6 6 1.0 P ,0.0001
treated or untreated IL-21 cells
B MFI NA 32.5 6 1.0 40.4 6 1.3 P ,0.0001
C Percentage of NA 60.2 6 6.4 146.0 6 12.7 P ,0.0001
increase in MFI
CTLA-4–Ig treated n 5 7 D Percentage of 0.22 6 0.03 1.3 6 0.1 2.5 6 0.6 P 5 0.09
mice IL-21 Cells
E MFI NA 27.3 6 0.8 29.2 6 0.5 P 5 0.07
F Percentage of NA 13.6 6 1.8 16.7 6 2.4 P 5 0.39
increase in MFI
CD28-deficient n 5 13 G Percentage of 0.18 6 0.04 1.5 6 0.1 1.5 6 0.2 P 5 0.78
DO11.10 T cells IL-21 Cells
H MFI NA 26.4 6 1.8 25.3 6 1.5 P 5 0.13
J Percentage of NA 8.5 6 1.6 10.9 6 2.7 P 5 0.17
increase in MFI
Flow cytometric measurements of IL-2 production in vivo by Ag-specific T cells in response to Ag stimulation in the presence or absence of CD28
costimulation. OVA was administered with or without LPS to mice 10–12 h before killing. Lanes A, D, and G show the percent of CD41, KJ1-261
cells that were IL-21. Lanes B, E, H show the MFI for IL-2 staining of only the CD41, KJ1-261, IL-21 cells. Lanes C, F, and J show the percent in-
crease in MFI for IL-2 staining of the total population of CD41, KJ1-261 cells derived from LNs of injected animals as compared to background
staining of CD41, KJ1-261 cells from uninjected animals. Lanes A, B, and C show pooled data from 12 independent experiments where mice were
transferred with wild-type DO11.10 T cells and were either treated with rat IgG Ab used as a control for CTLA-4–Ig, or were untreated. Lanes D,
E, and F show pooled data from three independent experiments where mice were transferred with wild-type DO11.10 T cells and were treated with
CTLA-4–Ig. Lanes G, H, and J show pooled data from four independent experiments where mice were transferred with CD28-deficient DO11.10
T cells. Treatment of these mice with CTLA-4–Ig did not further decrease IL-2 production (data not shown). The significance of differences in IL-2
production by DO11.10 T cells from mice injected with OVA alone and OVA plus LPS was tested with the paired two-tailed Student’s t test.230 Roles of Adjuvant, CD28, and IL-2 during Primary T Cell Responses In Vivo
number of other costimulatory molecules have been de-
scribed (22), it is reasonable to suggest that the residual T
cell proliferation seen in the absence of B7-CD28 signaling
is driven by alternative costimulatory pathways.
IL-2 Is a Critical T Cell Growth Factor In Vitro, but Is Not
Absolutely Required In Vivo. Multiple in vitro studies have
identified IL-2 as a major T cell growth factor (5) and pre-
vious reports have shown that CD41 T cells from IL-2–defi-
cient  mice proliferate less well in vitro than wild-type
CD41 T cells (17–19). Because of this and our finding that
adjuvants enhance in vivo IL-2 production by Ag-specific
T cells, it was of interest to determine whether IL-2 was
critical for the differences in clonal expansion observed
when Ag was injected alone or with adjuvant. As expected,
we found that IL-2–deficient, DO11.10 T cells proliferated
poorly in response to in vitro stimulation with OVA plus
APCs when compared with wild-type DO11.10 T cells
(Fig. 5 A). However, when IL-2–deficient DO11.10 T cells
were adoptively transferred into normal recipients, they
accumulated in the draining LNs to the same extent as
wild-type cells on day 3 after OVA injection (Fig. 5 B).
Surprisingly, injection of OVA with LPS, a condition where
wild-type cells produce more IL-2 (Fig. 4 B), caused the
IL-2–deficient DO11.10 T cells to accumulate in draining LNs
to a significantly higher level than wild-type cells (Fig. 5 B).
Although these results suggested that IL-2 was not re-
quired for maximal clonal expansion of naive T cells, it was
formally possible that the IL-2–deficient DO11.10 T cells
used for transfer were enriched for memory T cells that use
a growth factor other than IL-2. DO11.10 T cells from IL-
2–deficient donors contained more memory phenotype
cells (z40%) than DO11.10 T cells from normal donors
(10–30%). However, as shown in Fig. 6, FACSÒ-sorted,
CD45RBhigh DO11.10 T cells from IL-2–deficient or nor-
mal donors underwent a similar amount of clonal expan-
sion when transferred into normal recipients that were in-
jected with OVA alone, and responses by both populations
were enhanced by LPS. In fact, the phenotypically naive
populations clonally expanded to a greater degree than
their memory phenotype (CD45RBlow) counterparts.
A trivial explanation for the lack of a defect in clonal ex-
pansion in vivo could have been that the IL-2–deficient,
DO11.10 T cells responded to IL-2 produced by the recip-
ient’s T cells. To address this possibility, LN accumulation of
wild-type DO11.10 T cells in response to OVA administra-
tion with or without LPS in the presence of a neutralizing
anti–IL-2 mAb was measured. As shown in Fig. 7, DO11.10
T cells in mice injected with OVA and treated with anti–
IL-2 mAb or control rat IgG achieved identical levels of
LN accumulation on day 3, suggesting that IL-2 is not ab-
solutely required in vivo for the initial phase of Ag-driven
T cell clonal expansion. Moreover, on day 6, more DO11.10
T cells remained in the LNs of the anti–IL-2 mAb-treated
recipients than in the rat IgG-treated recipients (Figs. 7 and
8), and this difference was particularly dramatic when OVA
was injected with LPS (Fig. 8). Therefore, based on exper-
iments with IL-2–deficient T cells and wild-type T cells
blocked with anti–IL-2 mAb, we conclude that IL-2 does
not have an obligatory role in the initial phase of T cell
clonal expansion and may in fact have an inhibitory effect
on the long-term persistence of activated T cells.
IL-2 Sensitizes Ag-specific T Cells for Cell Death after Ag
Stimulation In Vivo. Previous studies have shown that IL-
2R signaling is required for activated T cells to become
sensitive to Fas-mediated killing (19, 23). Disruption of such
a death pathway could explain why IL-2–deficient, Ag-
specific T cells (Fig. 5 A) or wild-type T cells activated in
the presence of anti–IL-2 mAb (Fig. 7) persisted longer in
vivo after Ag stimulation. Because previous attempts to
identify apoptotic DO11.10 T cells in vivo were unsuc-
cessful (2), probably as a result of efficient disposal of apop-
totic cells by macrophages, we tested the ability of in vivo–
Figure 3. Effect of LPS on IL-2
protein production by Ag-specific
T cells. 2 mg of OVA were in-
jected without (OVA) or with LPS
(OVA/LPS) 10 h before killing.
LN cells were stained for IL-2 di-
rectly (A) or incubated in vitro for
2.5 h (B). (A) intracellular IL-2
protein was measured in the CD41,
KJ1-261  population by three-
color  flow cytometry as described
in Fig 2, B–D. (B) IL-2 protein
secreted into the supernatants dur-
ing the ex vivo culture was mea-
sured by ELISA. Each column
represents two mice and is shown
as the mean 6 range. No IL-2
could be detected in the culture
supernatants of LN cells recov-
ered from animals that were trans-
ferred with DO11.10 TCR trans-
genic T cells, but did not receive
OVA. The figure is representative
of two independent experiments.231 Khoruts et al.
activated T cells to survive in culture to determine whether
IL-2 plays a role in activation-induced cell death in this sys-
tem. LN cells, recovered from adoptively transferred mice
injected 3 d previously with OVA, were cultured for an
additional 3 d in the absence of any additional stimuli. While
in vivo Ag-activated, wild-type DO11.10 TCR transgenic
T cells died quickly in vitro, the IL-2–deficient DO11.10
TCR transgenic T cells persisted as well as unactivated T cells
(Fig 5 C and data not shown). These results suggest that
death signals dependent on the presence of IL-2 may be re-
ceived early after Ag activation in vivo.
Functional Response of IL-2–deficient DO11.10 T Cells after
Immunization with OVA and LPS. Because LPS had a greater
effect on clonal expansion of IL-2–deficient DO11.10 T cells
when compared with wild-type DO11.10 cells, it was of
interest to determine if IL-2 may play a role in the differen-
tiation of naive Ag-specific T cells during a primary im-
mune response. Mice were adoptively transferred with naive,
IL-2–sufficient  DO11.10 SCID T cells or FACSÒ-sorted
CD45RBhigh, IL-2–deficient DO11.10 T cells and left un-
treated or were immunized with OVA and LPS. On day 8
after immunization cells from the draining LNs were stim-
ulated with the OVA peptide in vitro and cytokines were
measured in the culture supernatants (Table 2). Naive, IL-
2–sufficient DO11.10 T cells produced IL-2 and IL-3, but
very little IFN-g or IL-5, lymphokines produced by differ-
entiated T cells. IL-2–sufficient DO11.10 T cells from im-
munized mice produced less IL-2 and IL-3 and detectable
amounts of IFN-g and IL-5, indicating that the DO11.10
T cells had differentiated in vivo. IL-2 was not detected in
Figure 4. Kinetics of blastogenesis of Ag-specific T cells is normal in the absence of CD28 costimulation, but IL-2 production and Ag-specific T cell
expansion are decreased and are not potentiated by LPS. Mice were adoptively transferred with wild-type (filled symbols) or CD28-deficient (open symbols)
DO11.10 cells and injected subcutaneously at different times with OVA with (triangles) or without LPS (circles). Data shown in B–D were obtained from one
experiment. Data shown in panel A covering earlier time points were from a separate experiment. C shows the kinetics of blastogenesis as determined by
the percent increase in forward light scatter (size) of CD41, KJ1-261 cells from injected mice as compared with CD41, KJ1-261 cells from uninjected
mice. Each point in A–C represents the mean 6 SD for 2–4 mice per group. D shows the fold increase in the number of Ag-specific T cells on day 3 af-
ter Ag injection, calculated as a ratio of the total number of Ag-specific T cells present in the draining LNs from Ag-injected animals divided by the total
number of Ag-specific T cells present in the same LNs in uninjected animals. Each column represents the mean of data obtained from four mice 6 SD.
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Figure 5. OVA-specific IL-2–
deficient T cells have defective
proliferative responses in vitro,
but not in vivo, and are resistant
to cell death. (A) Cells recovered
from mice adoptively transferred
with wild-type (filled circles) or IL-
2–deficient (open circles) DO11.10
T cells were incubated in vitro in
the presence of 0.5 mM OVA
peptide 323-339, for the indicated
number of days. At each time
point replicate wells were har-
vested and the cells were counted
and stained for CD4 and KJ1-26.
Mean fold increase 6 SD of the
total number of transgenic T cells
is shown. (B) Mice adoptively
transferred with wild-type (open
symbols) or IL-2–deficient (filled
symbols) DO11.10 T cells were immunized with OVA in the absence or in the presence of 150 mg of LPS. The total number of CD41, KJ1-261 T cells
was assessed as described in Fig. 1. Each point on the graph represents the mean 6 SE for five mice per group. (C) LN cells recovered from mice adoptively
transferred with wild-type (open symbols) or IL-2–deficient (filled symbols) DO11.10 T cells that were injected in vivo with either OVA (circles) or with
OVA/LPS (triangles) 3 d before the start of ex vivo culture in the absence of any additional Ag stimulation. The cells were stained at the indicated times
for CD4 and KJ1-26 and analyzed by flow cytometry. The mean percentage of initial viable input 6 SD of two animals per group is shown.
Figure 6. LPS enhances clonal
expansion of naive and memory
Ag-specific T cells with and with-
out IL-2 production. CD41 T
cells from wild-type or IL-2–defi-
cient  DO11.10 transgenic mice
were sorted into CD45RBhigh and
CD45RBlow cells and injected
into normal BALB/c mice. The
recipients were injected with 2
mg of OVA and 150 mg of LPS,
or 2 mg of OVA alone, or left
uninjected. (A) The histogram in
the upper panel shows CD45RB
staining of CD41 T cells from
the IL-2–deficient DO11.10 trans-
genic donor before sorting. The
histograms in the lower panel
show equal numbers of sorted
CD45RBhigh and CD45RBlow IL-
2–deficient CD41 T cells just
before the adoptive transfer. (B)
Total numbers of CD41, KJ1-
261 cells present in the draining
LNs on day 3 after Ag injection
are shown. Each column repre-
sents the mean 6 SD with two mice per group. Since both CD45RBhigh and CD45RBlow cells were obtained from the same sort and were transferred
into the same number of recipients, this figure also shows the relative contributions of naive and memory T cells to clonal expansion in the unsorted
adoptive transfer experiments. (C) As the baseline numbers of CD41, KJ1-261 T cells in the LNs of uninjected mice were different for each group, clonal
expansion was also represented as fold increase in CD41, KJ1-261 cells. The figure represents one of two experiments with similar results.
the cultures containing naive IL-2–deficient DO11.10 cells,
indicating that endogenous OVA-specific T cells did not
contribute significantly to cytokine production at this time
point. Very little IFN-g was seen in the cultures containing
IL-2–deficient DO11.10 T cells from immunized mice,
and IL-3 production was similar to that of naive DO11.10
T cells. In addition, the failure to produce large amounts of
IFN-g was not accompanied by significant skewing toward
a Th2 phenotype, as comparable amounts of IL-5 were
produced by IL-2–deficient and IL-2–sufficient DO11.10
cells from immunized mice. Therefore, unlike IL-2–suffi-
cient T cells, IL-2–deficient T cells did not differentiate
into IFN-g–producing T cells in vivo in response to im-
munization.
Discussion
We tested the idea that immunological adjuvants, such as
LPS, enhance Ag-induced T cell clonal expansion by im-
proving CD28 signaling and IL-2 production by Ag-acti-233 Khoruts et al.
vated T cells in vivo. Although LPS clearly enhanced IL-2
production and clonal expansion via CD28-dependent mech-
anisms, surprisingly, we found no evidence that IL-2 ac-
counted for the improvement in clonal expansion.
The fact that LPS only enhanced Ag-driven IL-2 pro-
duction and clonal expansion when CD28 was available for
B7 binding is consistent with the idea that the adjuvant ef-
fects of LPS are caused by B7 upregulation on APCs. We
have recently observed direct interactions between den-
dritic cells and Ag-specific T cells in the T cell areas of LNs
after s.c. OVA injection at a time point that coincides with
peak IL-2 production by the T cells (24). Previous studies
have shown that the dendritic cells that reside in resting
lymphoid tissues express no B7-1 and low levels of B7-2
(25), and that LPS rapidly induces both molecules (9, 25).
Therefore the suboptimal IL-2 production and clonal ex-
pansion that was observed in mice injected with OVA alone
could be caused by Ag-presentation by B7-2low resting
dendritic cells, whereas the improved responses observed in
the presence of LPS could be caused by B7-11, B7-2high–
activated dendritic cells.
The small amount of IL-2 production and clonal expan-
sion observed in the absence of CD28-mediated costimula-
tion may be explained by other costimulatory molecules. In-
deed, we (4) and others (26) have shown that inflammatory
cytokines, such as TNF-a and IL-1, mimic the effects of LPS
on the clonal expansion of T cells stimulated by Ag. How-
ever, the failure of LPS to enhance the clonal expansion of
Ag-stimulated, CD28-deficient T cells indicates that TNF-a
or IL-1 does not enhance T cell accumulation in a CD28-
independent fashion as described in a superantigen model
(27). The stimulatory effects of TNF-a and IL-1 on T cells
may operate indirectly through induction of CD40, which
has been shown to regulate B7 expression on APC (28).
In most cases, IL-2 production and clonal expansion
were correlated, as would be expected if the former caused
the latter. However, our finding that the initial clonal ex-
pansion of IL-2–deficient T cells was at least as large if not
larger, than that exhibited by IL-2–sufficient T cells, dem-
onstrates that IL-2 production is not necessary for maximal
clonal expansion. This interpretation is supported by the
observation of Kneitz et al. (19) that clonal expansion of su-
perantigen-specific T cells is normal in IL-2–deficient mice.
Thus, other growth factors may be more important for
driving in vivo clonal expansion, although as discussed be-
low IL-2 may participate. IL-15 is a candidate for such a
growth factor because it partially restores proliferation of
Ag-activated, IL-2R–deficient TCR transgenic T cells in
vitro (23). However, residual in vitro proliferation of IL-2–
deficient T cells in response to TCR stimulation does not
Figure 7. In vivo neutralization of IL-2 does not affect T cell clonal ex-
pansion and increases T cell persistence. Mice adoptively transferred with
wild-type DO11.10 T cells were treated with anti–IL-2 mAb S4B6 or rat
IgG as described in Materials and Methods and injected subcutaneously
with 2 mg of soluble OVA. The number of CD41, KJ1-261 cells present
in the draining LNs was determined 3 and 6 d after Ag injection. Each
point represents the mean 6 SE for five mice per group. The anti–IL-2
mAb treatment did not affect the numbers of CD41, KJ1-261 T cells on
day 3 in two other independent experiments. (Filled circles) OVA s.c. 1 rat
IgG; (open circles) OVA s.c. 1 anti–IL-2; (filled squares) T only.
Figure 8. Expansion of Ag-specific T cells after injection of Ag with
LPS is augmented in mice treated with anti–IL-2 mAb. Mice adoptively
transferred with wild-type DO11.10 T cells were treated with anti–IL-2
mAb S4B6 or rat IgG and injected subcutaneously with 2 mg OVA and
150 mg LPS. The number of CD41, KJ1-261 cells present in the draining
LNs was determined on day 6. Each bar represents the mean 6 SE with
five mice per group.234 Roles of Adjuvant, CD28, and IL-2 during Primary T Cell Responses In Vivo
depend on signals delivered through the common g chain (gc)
of the IL-2, IL-4, IL-7, IL-9, and IL-15 receptors (18), sug-
gesting that signal(s) other than IL-15 may be involved. Be-
cause proliferation of IL-2–deficient T cells has been shown
to be highly dependent on B7-derived costimulation (18),
and gc-deficient T cells benefit from CD28 signaling (29),
it is reasonable to suggest that the IL-2–independent growth
signal is another cytokine whose production is CD28-
dependent. Alternatively, CD28 signaling may drive prolif-
eration directly or upregulate other surface molecules that
deliver growth signals. Our finding that Ag-stimulated, IL-
2–deficient T cells did not become IFN-g–producing cells
in vivo, together with a similar in vitro result with IL-2R–
deficient T cells (23), indicate that IL-2 plays an important
role in T cell differentiation.
The normal initial in vivo clonal expansion of Ag-acti-
vated, IL-2–deficient, DO11.10 T cells was surprising be-
cause of the poor in vitro proliferative capacity of these
cells. It is difficult to believe that IL-2 is an important T cell
growth factor in vitro, but not in vivo. It is possible that
IL-2 is an important T cell growth factor in vivo at limiting
antigen doses. However, at the high antigen dose used
here, the growth factor function of IL-2 may be difficult to
reveal because IL-2 also sensitizes activated T cells for cell
death, perhaps as a consequence of the FasL–Fas interaction
(19, 23). This model suggests that in the presence of IL-2,
naive T cells would proliferate maximally because of the
synergy between autocrine IL-2 and an IL-2-, gcR-inde-
pendent growth signal, but would also become primed for
programmed cell death. In the absence of IL-2, T cells
would proliferate suboptimally because only the IL-2–inde-
pendent growth signal would be available, but the cells
would survive better because of the absence of IL-2–driven
cell death. The combination of reduced proliferation and
absence of IL-2-driven cell death could explain why IL-2–
deficient T cells accumulated to the same level as wild-type
cells on day 3. After day 3, proliferation would cease and
only T cells that were activated in the presence of IL-2
would be sensitive to death signals and die, while T cells
that proliferated in the absence of IL-2 would persist. This
would explain why on day 6 the number of IL-2–deficient
DO11.10 T cells present in LNs was considerably higher
than that of wild-type DO11.10 T cells. It is possible that
the IL-2–dependent death signal is not delivered efficiently
in vitro (few T cells undergo cell death after in vitro activa-
tion, data not shown). Thus, IL-2–deficient T cells would
proliferate poorly in vitro because only the activity of the
IL-2–independent growth factor would be present.
The paradoxical capacity of IL-2 to initially drive the prolif-
eration of naive T cells, and then the death of activated T cells,
was previously suggested by Lenardo et al. (30, 31) to provide
a negative feedback mechanism that prevents excessive ac-
cumulation of activated T cells. It is possible that the lethal
lymphoproliferative disease that occurs in IL-2–deficient mice
that have a normal T cell repertoire is the result of non–IL-2
growth signal-driven T cell expansion unchecked by IL-2–
mediated death. It is also interesting to note that this disease
does not occur in germ-free mice (32). Intestinal microbial
flora could provide not only a source of potentially cross-reac-
tive Ags, but also a source of adjuvants, which based on our
results with LPS, would heighten the production of B7-
dependent, non–IL-2 growth signals. In the absence of IL-2,
autoreactive T cells would then accumulate out of control due
to lack of constraint provided by IL-2–mediated cell death.
We thank Jennifer White for technical assistance and Rebecca Merica, Zong-Ming Chen, Dr. Elizabeth In-
gulli, and Dr. Paul Garside for helpful discussions.
Table 2. Cytokine Profile of Naive and Primed Wild-type and IL-2-deficient DO11.10 T Cells
Cytokine level per
DO11.10 T cell
Uninjected OVA/LPS injected
WT SCID DO11.10
T cells
IL-2 KO
CD45RBhigh
DO11.10 T cells
WT SCID DO11.10
T cells
IL-2 KO
CD45RBhigh
DO11.10 T cells
IL-2 fg/ml 6 SD 352.0 Undetectable 61.6 6 8.3 Undetectable
IL-3 ODu 6 SD 374.0 432.0 59.4 6 3.1 226.5 6 37.5
IL-5 ODu 6 SD Undetectable Undetectable 5.9 6 0.1 7.5 6 1.1
IFN-g fg/ml 6 SD Undetectable Undetectable 300.0 6 5.7 18.6 6 1.6
In vitro cytokine production profiles of IL-2–sufficient and IL-2–deficient DO11.10 T cells after in vivo immunization with OVA and LPS. Normal
BALB/c mice were transferred with IL-2–sufficient DO11.10 SCID cells or sorted IL-2–deficient CD45RBhigh DO11.10 cells and were either in-
jected with 2 mg OVA and 150 mg LPS or left uninjected. Mice were killed on 8 d, and LN cells were cultured with or without OVA peptide. In-
dicated cytokines were measured in 48-h culture supernatants as described in Materials and Methods. Cytokine concentrations were adjusted for the
input number of CD41, KJ1-261 T cells present in each well. No detectable cytokine was seen in the absence of OVA peptide stimulation. The re-
sults of this experiment are representative of two other similar experiments where unsorted wild-type and IL-2–deficient DO11.10 T cells were used.
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